Ameliorative effect of a nano chromium metal–organic framework on experimental diabetic chronic kidney disease

Fakharzadeh, Saideh; Kalanaky, Somayeh; Argani, Hassan; Dadashzadeh, Simin; Torbati, Peyman Mohammadi; Nazaran, Mohammad Hassan; Basiri, Abbas

doi:10.1002/ddr.21759

Cited by 4 publications

(5 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Albuminuria, including micro-albuminuria and macro-albuminuria, has been used both as a useful initial marker for kidney damage and a marker associated with an increased risk of progressive renal diseases [ 22 , 23 ]. However, a possible protective interaction effect is being increasingly reported for the interaction effect between chromium exposure and diabetic chronic kidney disease, based on improved glucose tolerance and insulin sensitivity [ 24 – 28 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Case-only approach applied in environmental epidemiology: 2 examples of interaction effect using the US National Health and Nutrition Examination Survey (NHANES) datasets

Moon

Kim

2022

BMC Med Res Methodol

View full text Add to dashboard Cite

Introduction By substituting the general ‘susceptibility factor’ concept for the conventional ‘gene’ concept in the case-only approach for gene-environment interaction, the case-only approach can also be used in environmental epidemiology. Under the independence between the susceptibility factor and environmental exposure, the case-only approach can provide a more precise estimate of an interaction effect. Methods Two analysis examples of the case-only approach in environmental epidemiology are provided using the 2015–2016 and 2017–2018 US National Health and Nutritional Examination Survey (NHANES): (i) the negative interaction effect between blood chromium level and glycohemoglobin level on albuminuria and (ii) the positive interaction effect between blood cobalt level and old age on albuminuria. The second part of the methods (theoretical backgrounds) summarized the logic and equations provided in previous studies about the case-only approach. Results (i) When a 1 μg/L difference of both blood chromium level (mcg/L) and a 1% difference in blood glycohemoglobin level coincide, the multiplicative interaction contrast ratio (ICRc/nc) was 0.72 (95% CI 0.35–1.60), with no statistical significance. However, when only the cases were analyzed, the case-only ICR (ICRCO) was 0.59 (95% CI 0.28–0.95), with a statistical significance (a negative interaction effect). (ii) When a 1 μg/L difference of both blood cobalt levels and a 1-year difference in age coincide, the multiplicative interaction contrast ratio (ICRc/nc) was 1.13 (95% CI 0.99–1.37), with no statistical significance. However, when only the cases were analyzed, the case-only ICR (ICRCO) was 1.21 (95% CI 1.06–1.51), with a statistical significance (a positive interaction effect). Discussion The discussion suggested the theoretical background and previous literature about the possible protective interaction effect between blood chromium levels and blood glycohemoglobin levels on the incidence of albuminuria and the possible aggravating interaction effect between blood cobalt levels and increasing ages on the incidence of albuminuria. If the independence assumption between a susceptibility factor and environmental exposure in a study with cases and non-cases is kept, the case-only approach can provide a more precise interaction effect estimate than conventional approaches with both cases and non-cases.

show abstract

Section: Discussionmentioning

confidence: 99%

“…This protective interaction effect of chromium on diabetic patients with nephropathy can be used for establishing a future effective treatment strategy for diabetic nephropathy. For example, a study reports a possible positive effect of prescribing a nano chromium metal-organic framework on diabetic chronic kidney disease patients [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Case-only approach applied in environmental epidemiology: 2 examples of interaction effect using the US National Health and Nutrition Examination Survey (NHANES) datasets

Moon

Kim

2022

BMC Med Res Methodol

View full text Add to dashboard Cite

show abstract

“…Metal organic frameworks have been widely used in various fields, including in the medical field [ 88 ]. A study demonstrated that metal organic frameworks effectively reduced the HOMA-IR index, BUN, uric acid and malondialdehyde in plasma samples of experimental DN [ 89 ]. At present, research has proven that BCc1, a nanochelate with iron chelating properties, has antitumor effects [ 90 ].…”

Section: Application Of Nanomaterials In Gn Treatmentmentioning

confidence: 99%

Application of nanotechnology in the treatment of glomerulonephritis: current status and future perspectives

Zhan,

Zhang,

Chen

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Glomerulonephritis (GN) is the most common cause of end-stage renal failure worldwide; in most cases, it cannot be cured and can only delay the progression of the disease. At present, the main treatment methods include symptomatic therapy, immunosuppressive therapy, and renal replacement therapy. However, effective treatment of GN is hindered by issues such as steroid resistance, serious side effects, low bioavailability, and lack of precise targeting. With the widespread application of nanoparticles in medical treatment, novel methods have emerged for the treatment of kidney diseases. Targeted transportation of drugs, nucleic acids, and other substances to kidney tissues and even kidney cells through nanodrug delivery systems can reduce the systemic effects and adverse reactions of drugs and improve treatment effectiveness. The high specificity of nanoparticles enables them to bind to ion channels and block or enhance channel gating, thus improving inflammation. This review briefly introduces the characteristics of GN, describes the treatment status of GN, systematically summarizes the research achievements of nanoparticles in the treatment of primary GN, diabetic nephropathy and lupus nephritis, analyzes recent therapeutic developments, and outlines promising research directions, such as gas signaling molecule nanodrug delivery systems and ultrasmall nanoparticles. The current application of nanoparticles in GN is summarized to provide a reference for better treatment of GN in the future. Graphical Abstract

show abstract

“…Chromium containing MOF synthesised using nanochelating technology after 8 weeks of treatment in diabetic rats decreased insulin resistance and improved creatinine clearance. 113 …”

Section: Possible Future Therapiesmentioning

confidence: 99%

“…Chromium containing MOF synthesised using nanochelating technology after 8 weeks of treatment in diabetic rats decreased insulin resistance and improved creatinine clearance. 113 Ethyl vanillin (EVA) Ethyl vanillin (EVA), an analogue of vanillin, is a common food additive and has antioxidant activity. In vivo and in vitro studies demonstrated that EVA may protect against DKD through inhibition of oxidative stress and apoptosis and the protective effect might be associated with the regulation of the activation of Nrf2.…”

Section: Hydrogen Sulphide (H2s)mentioning

confidence: 99%

Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future

Mallik

Chowdhury

2022

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is a leading cause of morbidity and mortality among people living with diabetes, and is one of the most important causes of end stage renal disease worldwide. In order to reduce progression of DKD, important management goals include treatment of hypertension, glycaemia and control of cardiovascular risk factors such as lipids, diet, smoking and exercise. Use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers has an established role in prevention of progression of DKD. A number of other agents such as endothelin-1 receptor antagonists and bardoxolone have had disappointing results. Recent studies have, however, suggested that newer antidiabetic agents such as sodium-glucose transporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 analogues have specific beneficial effects in patients with DKD. Indeed most recent guidance suggest that SGLT-2i drugs should be used early in DKD, irrespective of glucose control. A number of pathways are hypothesised for the development and progression of DKD, and have opened up a number of newer potential therapeutic targets. This article aims to discuss management of DKD with respect to seminal trials from the past, more recent trials informing the present and potential new therapeutic options that may be available in the future.

show abstract

Ameliorative effect of a nano chromium metal–organic framework on experimental diabetic chronic kidney disease

Cited by 4 publications

References 70 publications

Case-only approach applied in environmental epidemiology: 2 examples of interaction effect using the US National Health and Nutrition Examination Survey (NHANES) datasets

Case-only approach applied in environmental epidemiology: 2 examples of interaction effect using the US National Health and Nutrition Examination Survey (NHANES) datasets

Application of nanotechnology in the treatment of glomerulonephritis: current status and future perspectives

Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future

Contact Info

Product

Resources

About